CHMP issues negative opinion on Translarna renewal; PTC plans re-examination

PTC THERAPEUTICS, INC.

CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) for nmDMD.
Negative opinion follows EC request for re-review; PTC will request re-examination per EMA guidelines.
Marketing authorization remains in effect; Translarna expected on market through end of 2024 even if opinion upheld.
CEO Klein: 'STRIDE real-world evidence should not be ignored'; expert panel agreed evidence shows significant efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.